| 雷珠单抗临床应用新进展概述 |
| |
| 引用本文： | 高婧,刘迪丰,蔡林. 雷珠单抗临床应用新进展概述[J]. 中国药师, 2015, 0(3): 479-482 |
| |
| 作者姓名： | 高婧 刘迪丰 蔡林 |
| |
| 作者单位： | 解放军第181医院药剂科 广西桂林 541002;解放军第181医院药剂科;解放军第182医院药剂科 |
| |
| 摘 要： | 雷珠单抗(ranibizumab)是第二代人源化抗血管内皮生长因子(VEGF)重组鼠单克隆抗体片段,能与所有活性形式的VEGF-A结合,防止其与VEGFR1及VEGFR2结合,从而减少血管内皮细胞增殖和降低血管通透性,抑制新生血管生成。近年来,其临床应用范围不断扩大,新的观察结果和观点、理念不断涌现。现将近年来雷珠单抗在眼科临床应用的最新进展作一综述。
|
| 关 键 词： | 雷珠单抗 血管内皮生长因子抑制药 临床应用 进展 |
| 收稿时间： | 2014-08-25 |
| 修稿时间： | 2014-12-24 |
Recent Progress in Clinical Application of Ranibizumab |
| |
| Gao Jing,Liu Difeng and Cai Lin. Recent Progress in Clinical Application of Ranibizumab[J]. China Pharmacist, 2015, 0(3): 479-482 |
| |
| Authors: | Gao Jing Liu Difeng Cai Lin |
| |
| Affiliation: | Gao Jing;Liu Difeng;Cai Lin;Pharmaceutical Preparation Section,the 181st Hospital of People’s Liberation Army; |
| |
| Abstract: | ABSTRACT Ranibizumab is a recombinant rat monoclonal antibody fragment of the second generation humanized VEGF. Ranibizumab can bind all of active VEGF A to inhibit the bond between VEGF A and VEGFR1 or VEGFR2. As the results, the vascular endothelial proliferation and vascular permeability can be reduced, and the new vessels angiogenesis can be prevented. The article systematically searched and summarized the relative literatures to offer high quality evidences for the recent clinical application of ranibizumab in ophthalmology. |
| |
| Keywords: | Ranibizumab VEGF suppressant Clinical application Progress |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中国药师》浏览原始摘要信息 |
|
点击此处可从《中国药师》下载免费的PDF全文 |
